Announcements
- Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
- eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
- Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
As of last trade, Ovid Therapeutics Inc (1OT:STU) traded at 0.935, 49.60% above the 52 week low of 0.625 set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.925 |
---|---|
High | 0.94 |
Low | 0.925 |
Bid | 0.90 |
Offer | 0.965 |
Previous close | 0.925 |
Average volume | 0.00 |
---|---|
Shares outstanding | 70.94m |
Free float | 59.68m |
P/E (TTM) | -- |
Market cap | 71.65m USD |
EPS (TTM) | -0.7174 USD |
Data delayed at least 15 minutes, as of Jul 24 2024.
More ▼